(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia
Autor(es) : Roman-Gomez, J. (José)
Jimenez-Velasco, A. (A.)
Castillejo, J.A. (J.A.)
Aguirre, X. (Xavier)
Barrios, M. (M.)
Navarro, G. (Germán)
Molina, F.J. (Francisco J.)
Calasanz-Abinzano, M.J. (Maria Jose)
Prosper, F. (Felipe)
Heiniger, A. (A.)
Torres, A. (Antonio)
Palabras clave : Materias Investigacion::Ciencias de la Salud::Oncología
Fecha incorporación: 2004
Editorial : American Society of Hematology
Versión del editor: http://dx.doi.org/10.1182/blood-2004-03-0954
ISSN: 0006-4971
Cita: Roman-Gomez, J., Jimenez-Velasco, A., Castillejo, J. A., Agirre, X., Barrios, M., Navarro, G. et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 140(8): 2492-2498
Resumen
Promoter hypermethylation plays an important role in the inactivation of cancerrelated genes. This abnormality occurs early in leukemogenesis and seems to be associated with poor prognosis in acute lymphoblastic leukemia (ALL). To determine the extent of hypermethylation in ALL, we analyzed the methylation status of the CDH1, p73, p16, p15, p57, NES-1, DKK-3, CDH13, p14, TMS-1, APAF-1, DAPK, PARKIN, LATS-1, and PTEN genes in 251 consecutive ALL patients.Atotal of 77.3% of samples had at least 1 gene methylated, whereas 35.9% of cases had 4 or more genes methylated. Clinical features and complete remission rate did not differ among patients without methylated genes, patients with 1 to 3 methylated genes (methylated group A), or patients with more than 3 methylated genes (methylated group B). Estimated disease-free survival (DFS) and overall survival (OS) at 11 years were 75.5% and 66.1%, respectively, for the nonmethylated group; 37.2% and 45.5% for methylated group A; and 9.4% and 7.8% for methylated group B (P < .0001 and P .0004, respectively). Multivariate analysis demonstrated that the methylation profile was an independent prognostic factor in predicting DFS (P < .0001) and OS (P .003). Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in ALL
Enlace permanente: http://hdl.handle.net/10171/18564
Aparece en las colecciones: DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Ficheros en este registro:
Fichero:  2004_Blood_Roman-Gomez_Promoter hypermethylation of cancer-related genes is a strong independent prognostic factor in acute lymphoblastic leukemia.pdf
Descripción: 
Tamaño:  121,21 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.